| Year |
Citation |
Score |
| 2023 |
Chu Y, Hirst WD, Federoff HJ, Harms AS, Stoessl AJ, Kordower JH. Nigrostriatal tau pathology in parkinsonism and Parkinson's disease. Brain : a Journal of Neurology. PMID 38006313 DOI: 10.1093/brain/awad388 |
0.314 |
|
| 2023 |
Su D, Gan Y, Zhang Z, Cui Y, Zhang Z, Liu Z, Wang Z, Zhou J, Sossi V, Stoessl AJ, Wu T, Jing J, Feng T. Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 36799459 DOI: 10.1002/mds.29320 |
0.357 |
|
| 2022 |
Fu JF, Wegener T, Klyuzhin IS, Mannheim JG, McKeown MJ, Stoessl AJ, Sossi V. Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study. Neuroimage. Clinical. 36: 103246. PMID 36451352 DOI: 10.1016/j.nicl.2022.103246 |
0.393 |
|
| 2021 |
Kaasinen V, Vahlberg T, Stoessl AJ, Strafella AP, Antonini A. Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33955044 DOI: 10.1002/mds.28632 |
0.411 |
|
| 2020 |
Fu JF, Matarazzo M, McKenzie J, Neilson N, Vafai N, Dinelle K, Felicio AC, McKeown MJ, Stoessl AJ, Sossi V. Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33090574 DOI: 10.1002/mds.28340 |
0.374 |
|
| 2020 |
Pavel A, Murray DK, Stoessl AJ. COVID-19 and selective vulnerability to Parkinson's disease. The Lancet. Neurology. 19: 719. PMID 32822628 DOI: 10.1016/S1474-4422(20)30269-6 |
0.395 |
|
| 2020 |
Stoessl AJ. Immunotherapy for Parkinson's disease: stay tuned. Lancet Neurology. 19: 561-562. PMID 32562672 DOI: 10.1016/S1474-4422(20)30175-7 |
0.405 |
|
| 2020 |
Barker RA, Bjorklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells A, Fiandaca MS, Stoessl AJ, Eidelberg D, et al. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease. PMID 32508331 DOI: 10.3233/Jpd-202004 |
0.403 |
|
| 2019 |
Fu JF, Klyuzhin IS, McKeown MJ, Stoessl AJ, Sossi V. Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. Neuroimage. Clinical. 25: 102150. PMID 31901793 DOI: 10.1016/J.Nicl.2019.102150 |
0.387 |
|
| 2019 |
Alkabie S, Lange A, Manogaran P, Stoessl AJ, Costello F, Barton JJS. Optical coherence tomography of patients with Parkinson's disease and progressive supranuclear palsy. Clinical Neurology and Neurosurgery. 189: 105635. PMID 31855622 DOI: 10.1016/J.Clineuro.2019.105635 |
0.382 |
|
| 2019 |
Perlmutter JS, Stoessl AJ. Striatal DAT SPECT: Caveat Emptor! Movement Disorders. 34: 1430-1432. PMID 31769089 DOI: 10.1002/Mds.27811 |
0.411 |
|
| 2019 |
Sacheli MA, Neva JL, Lakhani B, Murray DK, Vafai N, Shahinfard E, English C, McCormick S, Dinelle K, Neilson N, McKenzie J, Schulzer M, McKenzie DC, Appel-Cresswell S, McKeown MJ, ... ... Stoessl AJ, et al. Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31584222 DOI: 10.1002/Mds.27865 |
0.463 |
|
| 2019 |
Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley LA. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31483900 DOI: 10.1002/Mds.27823 |
0.439 |
|
| 2019 |
Cherkasova MV, Corrow JC, Taylor A, Yeung SC, Stubbs JL, McKeown MJ, Appel-Cresswell S, Stoessl AJ, Barton JJS. Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. Parkinsonism & Related Disorders. PMID 31473085 DOI: 10.1016/J.Parkreldis.2019.08.014 |
0.398 |
|
| 2019 |
Fu JF, Klyuzhin I, McKenzie J, Neilson N, Shahinfard E, Dinelle K, McKeown MJ, Stoessl AJ, Sossi V. Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. Neuroimage. Clinical. 23: 101856. PMID 31091502 DOI: 10.1016/J.Nicl.2019.101856 |
0.42 |
|
| 2019 |
van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, ... ... Stoessl AJ, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 301-309. PMID 30984816 DOI: 10.1016/J.Dadm.2019.01.011 |
0.301 |
|
| 2019 |
Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, ... ... Stoessl AJ, et al. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. Journal of Parkinson's Disease. PMID 30829619 DOI: 10.3233/Jpd-191576 |
0.382 |
|
| 2019 |
Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, ... ... Stoessl AJ, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain : a Journal of Neurology. PMID 30808022 DOI: 10.1093/Brain/Awz023 |
0.356 |
|
| 2018 |
Matarazzo M, Wile D, Mackenzie M, Stoessl AJ. PET Molecular Imaging in Familial Parkinson's Disease. International Review of Neurobiology. 142: 177-223. PMID 30409253 DOI: 10.1016/Bs.Irn.2018.09.003 |
0.441 |
|
| 2018 |
Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease. PMID 30400107 DOI: 10.3233/Jpd-181471 |
0.363 |
|
| 2018 |
Klyuzhin IS, Fu JF, Hong A, Sacheli M, Shenkov N, Matarazzo M, Rahmim A, Stoessl AJ, Sossi V. Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. Plos One. 13: e0206607. PMID 30395576 DOI: 10.1371/Journal.Pone.0206607 |
0.356 |
|
| 2018 |
Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. Movement Disorders. 33: 1213-1227. PMID 30230624 DOI: 10.1002/Mds.27438 |
0.472 |
|
| 2018 |
Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion. 1-38. PMID 30016901 DOI: 10.1080/03007995.2018.1502165 |
0.367 |
|
| 2018 |
Fu JF, Klyuzhin I, Liu S, Shahinfard E, Vafai N, McKenzie J, Neilson N, Mabrouk R, Sacheli MA, Wile D, McKeown MJ, Stoessl AJ, Sossi V. Investigation of serotonergic Parkinson's disease-related covariance pattern using [C]-DASB/PET. Neuroimage. Clinical. 19: 652-660. PMID 29946508 DOI: 10.1016/J.Nicl.2018.05.022 |
0.394 |
|
| 2018 |
Liu SY, Wile DJ, Fu JF, Valerio J, Shahinfard E, McCormick S, Mabrouk R, Vafai N, McKenzie J, Neilson N, Perez-Soriano A, Arena JE, Cherkasova M, Chan P, Zhang J, ... ... Stoessl AJ, et al. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. The Lancet. Neurology. PMID 29456161 DOI: 10.1016/S1474-4422(18)30032-2 |
0.447 |
|
| 2018 |
Matarazzo M, Perez-Soriano A, Stoessl AJ. Dyskinesias and levodopa therapy: why wait? Journal of Neural Transmission (Vienna, Austria : 1996). PMID 29428995 DOI: 10.1007/S00702-018-1856-6 |
0.425 |
|
| 2017 |
Lai J, Heran MKS, Stoessl AJ, Gooderham PA. Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review. Movement Disorders Clinical Practice. 4: 607-611. PMID 30363443 DOI: 10.1002/Mdc3.12480 |
0.316 |
|
| 2017 |
Stoessl AJ. Challenges and unfulfilled promises in Parkinson's disease Lancet Neurology. 16: 866-867. PMID 29029841 DOI: 10.1016/S1474-4422(17)30334-4 |
0.403 |
|
| 2017 |
Straniero L, Guella I, Cilia R, Parkkinen L, Rimoldi V, Young A, Asselta R, Soldà G, Sossi V, Stoessl AJ, Priori A, Nishioka K, Hattori N, Follett J, Rajput A, et al. DNAJC12 and dopa-responsive non-progressive Parkinsonism. Annals of Neurology. PMID 28892570 DOI: 10.1002/Ana.25048 |
0.386 |
|
| 2017 |
Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, ... ... Stoessl AJ, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 1264-1310. PMID 28887905 DOI: 10.1002/Mds.27115 |
0.302 |
|
| 2017 |
Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, Farrer MJ, Nishioka K, Hattori N. Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. Neurobiology of Aging. PMID 28666710 DOI: 10.1016/J.Neurobiolaging.2017.05.022 |
0.435 |
|
| 2017 |
Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, ... ... Stoessl AJ, et al. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. The Lancet. Neurology. PMID 28336296 DOI: 10.1016/S1474-4422(17)30056-X |
0.462 |
|
| 2017 |
Liu SY, Chan P, Stoessl AJ. The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. Translational Neurodegeneration. 6: 4. PMID 28239455 DOI: 10.1186/S40035-017-0074-8 |
0.417 |
|
| 2016 |
Perrin AJ, Nosova E, Co K, Book A, Iu O, Silva V, Thompson C, McKeown MJ, Stoessl AJ, Farrer MJ, Appel-Cresswell S. Gender differences in Parkinson's disease depression. Parkinsonism & Related Disorders. PMID 28089265 DOI: 10.1016/J.Parkreldis.2016.12.026 |
0.354 |
|
| 2016 |
Kordower JH, Goetz CG, Chu Y, Halliday GM, Nicholson DA, Musial T, Marmion DJ, Stoessl AJ, Sossi V, Freeman TB, Olanow CW. Robust graft survival and normalized dopaminergic innervation does not obligate recovery in a pd patient. Annals of Neurology. PMID 27900791 DOI: 10.1002/Ana.24820 |
0.401 |
|
| 2016 |
Kurowska Z, Kordower JH, Stoessl AJ, Burke R, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S. Is Axonal Degeneration a Key Early Event in Parkinson's Disease? Journal of Parkinson's Disease. PMID 27497486 DOI: 10.3233/Jpd-160881 |
0.344 |
|
| 2016 |
Stoessl AJ, Mckeown MJ. Movement disorders. Handbook of Clinical Neurology. 136: 957-69. PMID 27430452 DOI: 10.1016/B978-0-444-53486-6.00049-1 |
0.374 |
|
| 2016 |
Stoessl AJ. Salivary gland biopsy for diagnosis of Parkinson's disease? The Lancet. Neurology. PMID 27102890 DOI: 10.1016/S1474-4422(16)30031-X |
0.365 |
|
| 2016 |
Stoessl AJ. Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias? Neurology. 86: 228. PMID 26718570 DOI: 10.1212/Wnl.0000000000002297 |
0.48 |
|
| 2016 |
Arena JE, Stoessl AJ. Optimizing diagnosis in Parkinson's disease: Radionuclide imaging. Parkinsonism & Related Disorders. 22: S47-51. PMID 26439947 DOI: 10.1016/J.Parkreldis.2015.09.029 |
0.482 |
|
| 2015 |
Lang AE, Stoessl AJ. The Saskatchewan Movement Disorders Program: Commitment Pays Off. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 42: 70-1. PMID 27482556 DOI: 10.1017/Cjn.2015.9 |
0.331 |
|
| 2015 |
Wile DJ, Dinelle K, Vafai N, McKenzie J, Tsui JK, Schaffer P, Ding YS, Farrer M, Sossi V, Stoessl AJ. A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26685774 DOI: 10.1002/Mds.26450 |
0.372 |
|
| 2015 |
Stoessl AJ. Imaging in Parkinson's disease: time to look below the neck. Brain : a Journal of Neurology. 138: 512-4. PMID 25713402 DOI: 10.1093/Brain/Awu392 |
0.403 |
|
| 2015 |
Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, ... ... Stoessl AJ, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. Jama Neurology. 72: 100-5. PMID 25401511 DOI: 10.1001/Jamaneurol.2014.2704 |
0.383 |
|
| 2015 |
Gustavsson EK, Trinh J, Guella I, Vilariño-Güell C, Appel-Cresswell S, Stoessl AJ, Tsui JK, McKeown M, Rajput A, Rajput AH, Aasly JO, Farrer MJ. DNAJC13 genetic variants in parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 273-8. PMID 25393719 DOI: 10.1002/Mds.26064 |
0.323 |
|
| 2015 |
Stoessl AJ. Central pharmacokinetics of levodopa: Lessons from imaging studies. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 73-9. PMID 25274160 DOI: 10.1002/Mds.26046 |
0.504 |
|
| 2014 |
Mestre TA, Armstrong MJ, Walsh R, Dakheel AA, Moro E, Stoessl AJ, Lang AE. Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease? Movement Disorders Clinical Practice. 1: 67-69. PMID 30363792 DOI: 10.1002/Mdc3.12009 |
0.349 |
|
| 2014 |
Appel-Cresswell S, Rajput AH, Sossi V, Thompson C, Silva V, McKenzie J, Dinelle K, McCormick SE, Vilariño-Güell C, Stoessl AJ, Dickson DW, Robinson CA, Farrer MJ, Rajput A. Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1684-7. PMID 25186792 DOI: 10.1002/Mds.26019 |
0.328 |
|
| 2014 |
Fujioka S, Boeve BF, Parisi JE, Tacik P, Aoki N, Strongosky AJ, Baker M, Sanchez-Contreras M, Ross OA, Rademakers R, Sossi V, Dickson DW, Stoessl AJ, Wszolek ZK. A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study. Parkinsonism & Related Disorders. 20: 1129-34. PMID 25175602 DOI: 10.1016/J.Parkreldis.2014.07.014 |
0.366 |
|
| 2014 |
Stoessl AJ, Halliday GM. DAT-SPECT diagnoses dopamine depletion, but not PD. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1705-6. PMID 25154601 DOI: 10.1002/Mds.26000 |
0.453 |
|
| 2014 |
Cherkasova MV, Stoessl AJ. A brain network response to sham surgery. The Journal of Clinical Investigation. 124: 3285-8. PMID 25036701 DOI: 10.1172/Jci77193 |
0.339 |
|
| 2014 |
Walker MD, Volta M, Cataldi S, Dinelle K, Beccano-Kelly D, Munsie L, Kornelsen R, Mah C, Chou P, Co K, Khinda J, Mroczek M, Bergeron S, Yu K, Cao LP, ... ... Stoessl AJ, et al. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. Journal of Parkinson's Disease. 4: 483-98. PMID 25000966 DOI: 10.3233/Jpd-140344 |
0.395 |
|
| 2014 |
Stoessl AJ, Lehericy S, Strafella AP. Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet (London, England). 384: 532-44. PMID 24954673 DOI: 10.1016/S0140-6736(14)60041-6 |
0.455 |
|
| 2014 |
Felicio AC, Dinelle K, Agarwal PA, McKenzie J, Heffernan N, Road JD, Appel-Cresswell S, Wszolek ZK, Farrer MJ, Schulzer M, Sossi V, Stoessl AJ. In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1197-201. PMID 24797316 DOI: 10.1002/Mds.25893 |
0.32 |
|
| 2014 |
Murray DK, Sacheli MA, Eng JJ, Stoessl AJ. The effects of exercise on cognition in Parkinson's disease: a systematic review. Translational Neurodegeneration. 3: 5. PMID 24559472 DOI: 10.1186/2047-9158-3-5 |
0.301 |
|
| 2014 |
Stoessl AJ. Gene therapy for Parkinson's disease: a step closer? Lancet (London, England). 383: 1107-9. PMID 24412047 DOI: 10.1016/S0140-6736(13)62108-X |
0.352 |
|
| 2014 |
Stoessl AJ. Developments in neuroimaging: positron emission tomography. Parkinsonism & Related Disorders. 20: S180-3. PMID 24262176 DOI: 10.1016/S1353-8020(13)70042-7 |
0.466 |
|
| 2014 |
Vilariño-Güell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, Yu I, Encarnacion M, Munsie LN, Tapia L, Gustavsson EK, Chou P, Tatarnikov I, Evans DM, Pishotta FT, ... ... Stoessl AJ, et al. DNAJC13 mutations in Parkinson disease. Human Molecular Genetics. 23: 1794-801. PMID 24218364 DOI: 10.1093/Hmg/Ddt570 |
0.384 |
|
| 2014 |
Chandran V, Stoessl AJ. Imaging in multiple system atrophy Neurology and Clinical Neuroscience. 2: 178-187. DOI: 10.1111/Ncn3.125 |
0.432 |
|
| 2013 |
Kuramoto L, Cragg J, Nandhagopal R, Mak E, Sossi V, de la Fuente-Fernández R, Stoessl AJ, Schulzer M. The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. Plos One. 8: e76595. PMID 24204641 DOI: 10.1371/Journal.Pone.0076595 |
0.411 |
|
| 2013 |
Walker MD, Dinelle K, Kornelsen R, Lee A, Farrer MJ, Stoessl AJ, Sossi V. Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. Ejnmmi Research. 3: 69. PMID 24088510 DOI: 10.1186/2191-219X-3-69 |
0.339 |
|
| 2013 |
Sharp ME, Viswanathan J, McKeown MJ, Appel-Cresswell S, Stoessl AJ, Barton JJ. Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude. Neuropsychologia. 51: 2679-89. PMID 23954375 DOI: 10.1016/J.Neuropsychologia.2013.08.008 |
0.392 |
|
| 2013 |
Murray D, Stoessl AJ. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacology & Therapeutics. 140: 306-18. PMID 23880289 DOI: 10.1016/J.Pharmthera.2013.07.009 |
0.38 |
|
| 2013 |
Sundal C, Fujioka S, Van Gerpen JA, Wider C, Nicholson AM, Baker M, Shuster EA, Aasly J, Spina S, Ghetti B, Roeber S, Garbern J, Tselis A, Swerdlow RH, Miller BB, ... ... Stoessl AJ, et al. Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism & Related Disorders. 19: 869-77. PMID 23787135 DOI: 10.1016/J.Parkreldis.2013.05.013 |
0.331 |
|
| 2013 |
Gonzalez ME, Dinelle K, Vafai N, Heffernan N, McKenzie J, Appel-Cresswell S, McKeown MJ, Stoessl AJ, Sossi V. Novel spatial analysis method for PET images using 3D moment invariants: applications to Parkinson's disease. Neuroimage. 68: 11-21. PMID 23246861 DOI: 10.1016/J.Neuroimage.2012.11.055 |
0.425 |
|
| 2013 |
Walker MD, Dinelle K, Kornelsen R, McCormick S, Mah C, Holden JE, Farrer MJ, Stoessl AJ, Sossi V. In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 33: 59-66. PMID 22929441 DOI: 10.1038/Jcbfm.2012.120 |
0.387 |
|
| 2013 |
Agarwal PA, Stoessl AJ. Biomarkers for trials of neuroprotection in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 71-85. PMID 22927101 DOI: 10.1002/Mds.25065 |
0.427 |
|
| 2013 |
Felicio AC, Stoessl AJ. Imaging of Dopamine and Serotonin Receptors and Transporters Imaging of the Human Brain in Health and Disease. 241-264. DOI: 10.1016/B978-0-12-418677-4.00010-5 |
0.424 |
|
| 2012 |
Stoessl AJ. Neuroimaging in the early diagnosis of neurodegenerative disease. Translational Neurodegeneration. 1: 5. PMID 23211024 DOI: 10.1186/2047-9158-1-5 |
0.308 |
|
| 2012 |
Agarwal P, Hogarth P, Hayflick S, MacLeod P, Kuriakose R, McKenzie J, Heffernan N, Dinelle K, Sossi V, Stoessl AJ. Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1698-9. PMID 23192926 DOI: 10.1002/Mds.25160 |
0.355 |
|
| 2012 |
Wray S, Self M, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin UM, Houlden H, Morris HR, Healy D, ... ... Stoessl AJ, et al. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. Plos One. 7: e43099. PMID 22952635 DOI: 10.1371/Journal.Pone.0043099 |
0.304 |
|
| 2012 |
Monchi O, Stoessl AJ. Imaging neural correlates of mild cognitive impairment in Parkinson's disease. The Lancet. Neurology. 11: 653-5. PMID 22814534 DOI: 10.1016/S1474-4422(12)70162-X |
0.325 |
|
| 2012 |
Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K. Neuroimaging: current role in detecting pre-motor Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 634-43. PMID 22508281 DOI: 10.1002/Mds.24976 |
0.393 |
|
| 2012 |
Stoessl AJ. Neuroimaging in Parkinson's disease: from pathology to diagnosis. Parkinsonism & Related Disorders. 18: S55-9. PMID 22166455 DOI: 10.1016/S1353-8020(11)70019-0 |
0.419 |
|
| 2012 |
Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Zhang J. DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiology of Aging. 33: 836.e5-7. PMID 22019052 DOI: 10.1016/J.Neurobiolaging.2011.09.015 |
0.409 |
|
| 2011 |
Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, McCormick S, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Stoessl AJ. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain : a Journal of Neurology. 134: 3290-8. PMID 22075521 DOI: 10.1093/Brain/Awr233 |
0.492 |
|
| 2011 |
Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. The Lancet. Neurology. 10: 987-1001. PMID 22014434 DOI: 10.1016/S1474-4422(11)70214-9 |
0.408 |
|
| 2011 |
Stoessl AJ, Brooks DJ, Eidelberg D. Milestones in neuroimaging. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 868-978. PMID 21626537 DOI: 10.1002/Mds.23679 |
0.441 |
|
| 2011 |
Stoessl AJ. Neuroimaging in Parkinson's disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 8: 72-81. PMID 21274687 DOI: 10.1007/S13311-010-0007-Z |
0.46 |
|
| 2011 |
de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, Mak E, McKenzie J, McCormick S, Sossi V, Ruth TJ, Lee CS, Calne DB, Stoessl AJ. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology. 69: 803-10. PMID 21246604 DOI: 10.1002/Ana.22284 |
0.472 |
|
| 2011 |
Stoessl AJ. Movement disorders: new insights into Parkinson's disease. The Lancet. Neurology. 10: 5-7. PMID 21163435 DOI: 10.1016/S1474-4422(10)70303-3 |
0.364 |
|
| 2011 |
Agarwal PA, Stoessl AJ. Advances in the role of neuroimaging to monitor disease progression in Parkinson's disease European Neurological Review. 6: 161-166. DOI: 10.17925/Enr.2011.06.03.161 |
0.46 |
|
| 2010 |
Kuriakose R, Stoessl AJ. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Progress in Brain Research. 184: 177-92. PMID 20887875 DOI: 10.1016/S0079-6123(10)84009-9 |
0.496 |
|
| 2010 |
Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernández R, Phillips AG, Stoessl AJ. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Archives of General Psychiatry. 67: 857-65. PMID 20679593 DOI: 10.1001/Archgenpsychiatry.2010.88 |
0.477 |
|
| 2010 |
Stoessl AJ. Continuous dopaminergic therapy in Parkinson disease: time to stride back? Annals of Neurology. 68: 3-5. PMID 20583222 DOI: 10.1002/Ana.22079 |
0.391 |
|
| 2010 |
Stoessl AJ. Parkin and Parkinson's disease: differentiated by non-dopaminergic dysfunction? Experimental Neurology. 225: 48-50. PMID 20450912 DOI: 10.1016/J.Expneurol.2010.04.015 |
0.441 |
|
| 2010 |
Stoessl AJ. Scans without evidence of dopamine deficiency: the triumph of careful clinical assessment. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 529-30. PMID 20425792 DOI: 10.1002/Mds.23138 |
0.358 |
|
| 2010 |
Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, Sossi V, McCormick S, Ruth TJ, Stoessl AJ. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse (New York, N.Y.). 64: 146-51. PMID 19852071 DOI: 10.1002/Syn.20708 |
0.385 |
|
| 2009 |
Stoessl AJ. Functional imaging studies of non-motoric manifestations of Parkinson's Disease. Parkinsonism & Related Disorders. 15: S13-6. PMID 20082973 DOI: 10.1016/S1353-8020(09)70771-0 |
0.455 |
|
| 2009 |
Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, McKenzie J, McCormick S, Samii A, Troiano A, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Calne DB, Stoessl AJ. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain : a Journal of Neurology. 132: 2970-9. PMID 19690093 DOI: 10.1093/brain/awp209 |
0.346 |
|
| 2009 |
de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse (New York, N.Y.). 63: 713-6. PMID 19391152 DOI: 10.1002/Syn.20653 |
0.498 |
|
| 2009 |
Sossi V, Dinelle K, Topping GJ, Holden JE, Doudet D, Schulzer M, Ruth TJ, Stoessl AJ, de la Fuente-Fernandez R. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. Journal of Neurochemistry. 109: 85-92. PMID 19183257 DOI: 10.1111/J.1471-4159.2009.05904.X |
0.455 |
|
| 2009 |
Farrer MJ, Hulihan MM, Kachergus JM, Dächsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, et al. DCTN1 mutations in Perry syndrome. Nature Genetics. 41: 163-5. PMID 19136952 DOI: 10.1038/Ng.293 |
0.306 |
|
| 2009 |
Stoessl AJ. Radionuclide scanning to diagnose Parkinson disease: is it cost-effective? Nature Clinical Practice. Neurology. 5: 10-1. PMID 19065134 DOI: 10.1038/Ncpneuro0986 |
0.342 |
|
| 2009 |
Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism & Related Disorders. 15: 539-41. PMID 19041274 DOI: 10.1016/J.Parkreldis.2008.10.008 |
0.348 |
|
| 2009 |
Troiano AR, de la Fuente-Fernandez R, Sossi V, Schulzer M, Mak E, Ruth TJ, Stoessl AJ. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology. 72: 1211-6. PMID 19020294 DOI: 10.1212/01.wnl.0000338631.73211.56 |
0.39 |
|
| 2009 |
Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 336-43. PMID 19006186 DOI: 10.1002/Mds.22208 |
0.326 |
|
| 2009 |
Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism & Related Disorders. 15: 300-6. PMID 18804399 DOI: 10.1016/J.Parkreldis.2008.07.010 |
0.404 |
|
| 2009 |
Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L, Lechevalier B, Calne DB, Personett DA, Hulihan M, Kachergus J, Rademakers R, Baker MC, Grantier LL, Sujith OK, et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism & Related Disorders. 15: 281-6. PMID 18723384 DOI: 10.1016/J.Parkreldis.2008.07.005 |
0.302 |
|
| 2008 |
Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V, Ruth TJ, Strongosky A, Farrer MJ, Wszolek ZK, Stoessl AJ. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology. 71: 1790-5. PMID 19029519 DOI: 10.1212/01.wnl.0000335973.66333.58 |
0.355 |
|
| 2008 |
Nandhagopal R, McKeown MJ, Stoessl AJ. Functional imaging in Parkinson disease. Neurology. 70: 1478-88. PMID 18413571 DOI: 10.1212/01.Wnl.0000310432.92489.90 |
0.408 |
|
| 2008 |
Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. The Lancet. Neurology. 7: 400-8. PMID 18387850 DOI: 10.1016/S1474-4422(08)70065-6 |
0.388 |
|
| 2008 |
Stoessl AJ. Potential therapeutic targets for Parkinson's disease Expert Opinion On Therapeutic Targets. 12: 425-436. PMID 18348679 DOI: 10.1517/14728222.12.4.425 |
0.363 |
|
| 2008 |
Martin WR, Wieler M, Stoessl AJ, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Annals of Neurology. 63: 388-94. PMID 18240153 DOI: 10.1002/Ana.21320 |
0.43 |
|
| 2007 |
Stoessl AJ. Positron emission tomography in premotor Parkinson's disease. Parkinsonism & Related Disorders. 13: S421-4. PMID 18267275 DOI: 10.1016/S1353-8020(08)70041-5 |
0.499 |
|
| 2007 |
Hauser RA, Rascol O, Korczyn AD, Stoessl AJ, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa Movement Disorders. 22: 2409-2417. PMID 17894339 DOI: 10.1002/Mds.21743 |
0.382 |
|
| 2007 |
Sossi V, de la Fuente-Fernández R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Annals of Neurology. 62: 468-74. PMID 17886297 DOI: 10.1002/Ana.21204 |
0.477 |
|
| 2007 |
Stoessl AJ. Gene therapy for Parkinson's disease: early data. Lancet (London, England). 369: 2056-8. PMID 17586286 DOI: 10.1016/S0140-6736(07)60957-X |
0.351 |
|
| 2007 |
Postuma RB, Wolfson C, Rajput A, Stoessl AJ, Martin WR, Suchowersky O, Chouinard S, Panisset M, Jog MS, Grimes DA, Marras C, Lang AE. Is there seasonal variation in risk of Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1097-101. PMID 17486603 DOI: 10.1002/Mds.21272 |
0.364 |
|
| 2007 |
Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 9: 176-85. PMID 17334853 DOI: 10.1007/S11307-007-0098-Z |
0.395 |
|
| 2007 |
Gunzler SA, Stoessl AJ, Egan RA, Weleber RG, Wang P, Nutt JG. Joubert syndrome surviving to adulthood associated with a progressive movement disorder. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 262-5. PMID 17149728 DOI: 10.1002/Mds.21263 |
0.33 |
|
| 2006 |
de la Fuente-Fernández R, Lidstone S, Stoessl AJ. Placebo effect and dopamine release. Journal of Neural Transmission. Supplementum. 415-8. PMID 17017561 |
0.367 |
|
| 2006 |
Mercado R, Constantoyannis C, Mandat T, Kumar A, Schulzer M, Stoessl AJ, Honey CR. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1457-61. PMID 16721750 DOI: 10.1002/Mds.20935 |
0.342 |
|
| 2006 |
Koochesfahani KM, de la Fuente-Fernández R, Sossi V, Schulzer M, Yatham LN, Ruth TJ, Blinder S, Stoessl AJ. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 970-5. PMID 16570297 DOI: 10.1002/Mds.20857 |
0.493 |
|
| 2006 |
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, ... ... Stoessl AJ, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology. 59: 459-66. PMID 16429411 DOI: 10.1002/Ana.20737 |
0.302 |
|
| 2006 |
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, ... ... Stoessl AJ, et al. Erratum: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease (Annals of Neurology (2006) 59 (459-466)) Annals of Neurology. 60. DOI: 10.1002/Ana.21061 |
0.328 |
|
| 2005 |
Lang AE, Miyasaki J, Olanow CW, Stoessl AJ, Suchowersky O. Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 32: 277-86. PMID 16225167 DOI: 10.1017/S0317167100004145 |
0.408 |
|
| 2005 |
Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain : a Journal of Neurology. 128: 2777-85. PMID 16081470 DOI: 10.1093/Brain/Awh607 |
0.473 |
|
| 2005 |
Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ. Positron emission tomography after fetal transplantation in Huntington's disease. Annals of Neurology. 58: 331-7. PMID 16049929 DOI: 10.1002/Ana.20564 |
0.378 |
|
| 2005 |
Au WL, Adams JR, Troiano AR, Stoessl AJ. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Research. Molecular Brain Research. 134: 24-33. PMID 15790527 DOI: 10.1016/J.Molbrainres.2004.09.028 |
0.423 |
|
| 2005 |
Calne D, Schulzer M, Mak E, Stoessl AJ. Treatment for the progression of Parkinson's disease. The Lancet. Neurology. 4: 206. PMID 15778097 DOI: 10.1016/S1474-4422(05)70026-0 |
0.396 |
|
| 2005 |
Stoessl AJ, McGeer PL. Hot spots: can positron emission tomography offer insights into the pathogenesis of PD? Annals of Neurology. 57: 161-2. PMID 15668974 DOI: 10.1002/Ana.20382 |
0.34 |
|
| 2005 |
Lidstone SC, de la Fuente-Fernandez R, Stoessl AJ. The placebo response as a reward mechanism Seminars in Pain Medicine. 3: 37-42. DOI: 10.1016/J.Spmd.2005.02.004 |
0.433 |
|
| 2004 |
Lee CS, Schulzer M, de la Fuente-Fernández R, Mak E, Kuramoto L, Sossi V, Ruth TJ, Calne DB, Stoessl AJ. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Archives of Neurology. 61: 1920-5. PMID 15596613 DOI: 10.1001/Archneur.61.12.1920 |
0.453 |
|
| 2004 |
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 44: 601-7. PMID 15541309 DOI: 10.1016/J.Neuron.2004.11.005 |
0.375 |
|
| 2004 |
de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain : a Journal of Neurology. 127: 2747-54. PMID 15329355 DOI: 10.1093/Brain/Awh290 |
0.473 |
|
| 2004 |
Kumar A, Calne SM, Schulzer M, Mak E, Wszolek Z, Van Netten C, Tsui JK, Stoessl AJ, Calne DB. Clustering of Parkinson disease: shared cause or coincidence? Archives of Neurology. 61: 1057-60. PMID 15262735 DOI: 10.1001/Archneur.61.7.1057 |
0.305 |
|
| 2004 |
De La Fuente-Fernández R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: Clues from Parkinson's disease Biological Psychiatry. 56: 67-71. PMID 15231437 DOI: 10.1016/J.Biopsych.2003.11.019 |
0.433 |
|
| 2004 |
Furtado S, Payami H, Lockhart PJ, Hanson M, Nutt JG, Singleton AA, Singleton A, Bower J, Utti RJ, Bird TD, de la Fuente-Fernandez R, Tsuboi Y, Klimek ML, Suchowersky O, Hardy J, ... ... Stoessl AJ, et al. Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Movement Disorders : Official Journal of the Movement Disorder Society. 19: 622-9. PMID 15197699 DOI: 10.1002/Mds.20074 |
0.427 |
|
| 2004 |
De La Fuente-Fernandez R, Stoessl AJ. The Biochemical Bases of the Placebo Effect Science and Engineering Ethics. 10: 143-150. PMID 14986780 DOI: 10.1007/S11948-004-0071-Z |
0.459 |
|
| 2004 |
De La Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: A probabilistic model Brain. 127: 888-899. PMID 14960500 DOI: 10.1093/Brain/Awh102 |
0.45 |
|
| 2003 |
Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease Experimental Neurology. 184. PMID 14597329 DOI: 10.1016/J.Expneurol.2003.08.008 |
0.394 |
|
| 2003 |
Stoessl AJ. Agonizing over dopaminergic replacement therapy - Lessons from animal models of Parkinson's disease Experimental Neurology. 183: 1-3. PMID 12957481 DOI: 10.1016/S0014-4886(03)00184-5 |
0.398 |
|
| 2003 |
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology. 54: 403-14. PMID 12953276 DOI: 10.1002/Ana.10720 |
0.369 |
|
| 2003 |
Stoessl AJ, Lee CS, De La Fuente-Fernandez R. New concepts and tools in imaging for the study of neurodegenerative disease Journal of Neural Transmission, Supplement. 157-166. PMID 12946054 |
0.319 |
|
| 2003 |
Kumar A, Mann S, Sossi V, Ruth TJ, Stoessl AJ, Schulzer M, Lee CS. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain : a Journal of Neurology. 126: 2648-55. PMID 12937076 DOI: 10.1093/Brain/Awg270 |
0.413 |
|
| 2003 |
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology. 54: 93-101. PMID 12838524 DOI: 10.1002/Ana.10609 |
0.458 |
|
| 2003 |
McCormick SE, Stoessl AJ. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia Neuroscience. 119: 547-555. PMID 12770567 DOI: 10.1016/S0306-4522(03)00170-2 |
0.309 |
|
| 2003 |
De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, Ruth TJ, Stoessl AJ. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (New York, N.Y.). 49: 20-8. PMID 12710012 DOI: 10.1002/Syn.10199 |
0.382 |
|
| 2003 |
Huang Z, de la Fuente-Fernández R, Stoessl AJ. Etiology of Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 30: S10-8. PMID 12691472 DOI: 10.1017/S0317167100000032 |
0.384 |
|
| 2003 |
Inkster LM, Eng JJ, MacIntyre DL, Stoessl AJ. Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair Movement Disorders. 18: 157-162. PMID 12539208 DOI: 10.1002/Mds.10299 |
0.356 |
|
| 2003 |
van Kampen JM, Stoessl AJ. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience. 116: 307-14. PMID 12535962 DOI: 10.1016/S0306-4522(02)00548-1 |
0.766 |
|
| 2003 |
De La Fuente-Fernández RD, Lim AS, Sossi V, Adam MJ, Ruth TJ, Calne DB, Stoessl AJ, Lee CS. Age and severity of nigrostriatal damage at onset of Parkinson's disease Synapse. 47: 152-158. PMID 12454953 DOI: 10.1002/Syn.10160 |
0.398 |
|
| 2003 |
Stoessl AJ, de la Fuente-Fernández R. Dopamine receptors in Parkinson's disease: imaging studies Advances in Neurology. 91: 65-71. PMID 12442664 |
0.391 |
|
| 2002 |
De La Fuente-Fernández R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders Lancet Neurology. 1: 85-91. PMID 12849512 DOI: 10.1016/S1474-4422(02)00038-8 |
0.345 |
|
| 2002 |
Dunn HG, Stoessl AJ, Ho HH, MacLeod PM, Poskitt KJ, Doudet DJ, Schulzer M, Blackstock D, Dobko T, Koop B, De Amorim GV. Rett Syndrome: Investigation of nine patients, including PET scan Canadian Journal of Neurological Sciences. 29: 345-357. PMID 12463490 DOI: 10.1017/S0317167100002213 |
0.338 |
|
| 2002 |
De la Fuente-Fernández R, Stoessl AJ. The biochemical bases for reward: Implications for the placebo effect Evaluation and the Health Professions. 25: 387-398. PMID 12449082 DOI: 10.1177/0163278702238052 |
0.383 |
|
| 2002 |
De la Fuente-Fernández R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ. Dopamine release in human ventral striatum and expectation of reward Behavioural Brain Research. 136: 359-363. PMID 12429397 DOI: 10.1016/S0166-4328(02)00130-4 |
0.461 |
|
| 2002 |
Yatham LN, Liddle PF, Lam RW, Shiah IS, Lane C, Stoessl AJ, Sossi V, Ruth TJ. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. The American Journal of Psychiatry. 159: 1718-23. PMID 12359678 DOI: 10.1176/Appi.Ajp.159.10.1718 |
0.409 |
|
| 2002 |
Pal PK, Leung J, Hedrich K, Samii A, Lieberman A, Nausieda PA, Calne DB, Breakefield XO, Klein C, Stoessl AJ. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 789-94. PMID 12210877 DOI: 10.1002/Mds.10133 |
0.359 |
|
| 2002 |
De la Fuente-Fernández R, Stoessl AJ. Parkinson's disease: Imaging update Current Opinion in Neurology. 15: 477-482. PMID 12151846 DOI: 10.1097/00019052-200208000-00012 |
0.476 |
|
| 2002 |
Fuente-Fernández Rdl, Stoessl AJ. The placebo effect in Parkinson's disease Trends in Neurosciences. 25: 302-306. PMID 12086748 DOI: 10.1016/S0166-2236(02)02181-1 |
0.406 |
|
| 2002 |
Lu JQ, Stoessl AJ. Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. Neuroscience. 112: 261-6. PMID 12044444 DOI: 10.1016/S0306-4522(02)00081-7 |
0.36 |
|
| 2002 |
Sossi V, De la Fuente-Fernández R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ. Increase in dopamine turnover occurs early in Parkinson's disease: Evidence from a new modeling approach to PET 18F-fluorodopa data Journal of Cerebral Blood Flow and Metabolism. 22: 232-239. PMID 11823721 |
0.395 |
|
| 2002 |
Stoessl AJ. Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it? Movement Disorders : Official Journal of the Movement Disorder Society. 16: 804-6. PMID 11746608 DOI: 10.1002/Mds.1192 |
0.474 |
|
| 2001 |
De La Fuente-Fernández R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, Stoessl AJ. Apomorphine-induced changes in synaptic dopamine levels: Positron emission tomography evidence for presynaptic inhibition Journal of Cerebral Blood Flow and Metabolism. 21: 1151-1159. PMID 11598492 DOI: 10.1097/00004647-200110000-00003 |
0.471 |
|
| 2001 |
De la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease Science. 293: 1164-1166. PMID 11498597 DOI: 10.1126/Science.1060937 |
0.502 |
|
| 2001 |
de la Fuente-Fernández R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology. 49: 298-303. PMID 11261503 DOI: 10.1002/Ana.65.Abs |
0.471 |
|
| 2001 |
Stoessl AJ. Antisense strategies for the treatment of neurological disease Expert Opinion On Therapeutic Patents. 11: 547-562. DOI: 10.1517/13543776.11.4.547 |
0.301 |
|
| 2001 |
De La Fuente-Fernández R, Lu J, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover Annals of Neurology. 49: 298-303. DOI: 10.1002/Ana.65 |
0.477 |
|
| 2000 |
Van Kampen JM, Stoessl AJ. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. 101: 629-35. PMID 11113312 DOI: 10.1016/S0306-4522(00)00412-7 |
0.746 |
|
| 2000 |
Van Kampen JM, McGeer EG, Stoessl AJ. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. Synapse (New York, N.Y.). 37: 171-8. PMID 10881039 DOI: 10.1002/1098-2396(20000901)37:3<171::Aid-Syn1>3.0.Co;2-R |
0.757 |
|
| 2000 |
De La Fuente-Fernández R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ. Nigrostriatal dopamine system and motor lateralization Behavioural Brain Research. 112: 63-68. PMID 10862936 DOI: 10.1016/S0166-4328(00)00165-0 |
0.319 |
|
| 2000 |
Van Kampen JM, Stoessl AJ. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience. 98: 61-7. PMID 10858612 DOI: 10.1016/S0306-4522(00)00090-7 |
0.755 |
|
| 2000 |
Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, De La Fuente-Fernandez R, Calne DB, Stoessl AJ. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Annals of Neurology. 47: 493-503. PMID 10762161 DOI: 10.1002/1531-8249(200004)47:4<493::Aid-Ana13>3.0.Co;2-4 |
0.439 |
|
| 1999 |
Samii A, Markopoulou K, Wszolek ZK, Sossi V, Dobko T, Mak E, Calne DB, Stoessl AJ. PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology. 53: 2097-102. PMID 10599788 |
0.324 |
|
| 1998 |
Wang Y, Chan GLY, Holden JE, Dobko T, Mak E, Schulzer M, Huser JM, Snow BJ, Ruth TJ, Calne DB, Stoessl AJ. Age-dependent decline of dopamine D1 receptors in human brain: A PET study Synapse. 30: 56-61. PMID 9704881 DOI: 10.1002/(Sici)1098-2396(199809)30:1<56::Aid-Syn7>3.0.Co;2-J |
0.383 |
|
| 1998 |
Kishore A, Nygaard TG, De La Fuente-Fernandez R, Naini AB, Schulzer M, Mak E, Ruth TJ, Calne DB, Snow BJ, Stoessl AJ. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa- responsive dystonia measured with [11C]-raclopride and positron-emission tomography Neurology. 50: 1028-1032. PMID 9566390 |
0.301 |
|
| 1997 |
Van Kampen J, Stoessl AJ. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: Evidence for a novel CCK receptor subtype? Neuropharmacology. 36: 1679-1688. PMID 9517439 DOI: 10.1016/S0028-3908(97)00168-8 |
0.735 |
|
| 1997 |
Stoessl AJ, James KA, Napier BJ. The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat Neuropharmacology. 36: 93-99. PMID 9144645 DOI: 10.1016/S0028-3908(96)00163-3 |
0.31 |
|
| 1997 |
Newman DD, Rajakumar N, Flumerfelt BA, Stoessl AJ. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. Neuroreport. 8: 669-72. PMID 9106744 |
0.319 |
|
| 1997 |
Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. Pallidotomy for tardive dyskinesia Lancet. 349: 777-778. PMID 9074585 DOI: 10.1016/S0140-6736(05)60203-6 |
0.39 |
|
| 1996 |
Stoessl AJ, Rajakumar N. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. Synapse (New York, N.Y.). 24: 256-61. PMID 8923666 DOI: 10.1002/(Sici)1098-2396(199611)24:3<256::Aid-Syn8>3.0.Co;2-D |
0.302 |
|
| 1996 |
Van Kampen J, Frydryszak H, Stoessl AJ. Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat European Journal of Pharmacology. 298: 7-15. PMID 8867913 DOI: 10.1016/0014-2999(95)00767-9 |
0.412 |
|
| 1996 |
Stoessl AJ. Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade Parkinsonism and Related Disorders. 2: 167-175. DOI: 10.1016/S1353-8020(96)00022-3 |
0.409 |
|
| 1995 |
Stoessl AJ, Brackstone M, Rajakumar N, Gibson CJ. Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Research. 700: 115-20. PMID 8624700 DOI: 10.1016/0006-8993(95)00940-R |
0.375 |
|
| 1994 |
Stoessl AJ. Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone European Journal of Pharmacology. 259: 301-303. PMID 7982457 DOI: 10.1016/0014-2999(94)90657-2 |
0.385 |
|
| 1994 |
Stoessl AJ. Localization of striatal and nigral tachykinin receptors in the rat Brain Research. 646: 13-18. PMID 7519961 DOI: 10.1016/0006-8993(94)90052-3 |
0.363 |
|
| 1994 |
Stoessl AJ, Polanski E, Frydryszak H. Effects of ageing on tachykinin function in the basal ganglia. Brain Research. 632: 21-8. PMID 7511976 DOI: 10.1016/0006-8993(93)91133-D |
0.314 |
|
| 1993 |
Stoessl AJ, Szczutkowski E, Glenn B, Watson I. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Research. 565: 254-62. PMID 1668812 DOI: 10.1016/0006-8993(91)91657-M |
0.346 |
|
| 1992 |
Stoessl AJ. Prevention and management of late stage complications in Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 19: 113-6. PMID 1571855 |
0.355 |
|
| 1991 |
Stoessl AJ, Szczutkowski E. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat Brain Research. 558: 289-295. PMID 1685934 DOI: 10.1016/0006-8993(91)90780-Y |
0.311 |
|
| 1987 |
Calne DB, Stoessl AJ. Transmitter receptor alterations in Parkinson's disease. Advances in Neurology. 45: 45-9. PMID 2881449 |
0.322 |
|
| 1986 |
Suchowersky O, Hayden MR, Martin WR, Stoessl AJ, Hildebrand AM, Pate BD. Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 33-44. PMID 2973557 DOI: 10.1002/Mds.870010105 |
0.335 |
|
| 1985 |
Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature. 317: 246-8. PMID 3876510 DOI: 10.1038/317246A0 |
0.449 |
|
| 1985 |
Stoessl AJ, Mak E, Calne D. (+)-4-Propyl-9-Hydroxynaphthoxazine (Phno), A New Dopaminomimetic, In Treatment Of Parkinsonism The Lancet. 326: 1330-1331. PMID 2866388 DOI: 10.1016/S0140-6736(85)92627-3 |
0.394 |
|
| Show low-probability matches. |